Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease

Min Ho Nam, Moosung Park, Hyeri Park, Youngjae Kim, Seulki Yoon, Vikram Shahaji Sawant, Ji Won Choi, Jong Hyun Park, Ki Duk Park, Sun Joon Min, Changjoon Lee, Hyunah Choo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To develop novel, selective, and reversible MAO-B inhibitors for safer treatment of Parkinson's disease, benzothiazole and benzoxazole derivatives with indole moiety were designed and synthesized. Most of the synthesized compounds showed inhibitory activities against MAO-B and selectivity over MAO-A. The most active compound was compound 5b, 6-fluoro-2-(1-methyl-1H-indol-5-yl)benzo[d]thiazole with an IC50 value of 28 nM with no apparent effect on MAO-A activity at 10 μM. Based on the reversibility assay, compound 5b turned out to be fully reversible with over 95% of recovery of enzyme activity after washout of the compound. Compound 5b showed a reasonable stability in human liver microsomes and did not affect the activities of CYP isozymes, suggesting an absence of high-risk drug-drug interaction. In an in vivo MPTP-induced animal model of Parkinson's disease, oral administration of compound 5b showed neuroprotection of nigrostriatal dopaminergic neurons as revealed by tyrosine hydroxylase staining and prevention of MPTP-induced parkinsonism as revealed by motor behavioral assay of vertical grid test. In summary, the novel, reversible, and selective MAO-B inhibitor compound 5b was synthesized and characterized. We propose compound 5b as an effective therapeutic compound for relieving parkinsonism.

Original languageEnglish
Pages (from-to)1519-1529
Number of pages11
JournalACS Chemical Neuroscience
Volume8
Issue number7
DOIs
Publication statusPublished - 2017 Jul 19

Fingerprint

Benzothiazoles
Benzoxazoles
Monoamine Oxidase Inhibitors
Monoamine Oxidase
Parkinson Disease
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MPTP Poisoning
Assays
Drug interactions
Therapeutics
Thiazoles
Dopaminergic Neurons
Tyrosine 3-Monooxygenase
Enzyme activity
Parkinsonian Disorders
Liver Microsomes
Drug Interactions
Liver
Isoenzymes
Inhibitory Concentration 50

Keywords

  • benzothiazole
  • benzoxazole
  • MAO-B
  • MAO-B inhibitor
  • MPTP-induced animal model
  • Parkinson's disease

ASJC Scopus subject areas

  • Physiology
  • Biochemistry
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease. / Nam, Min Ho; Park, Moosung; Park, Hyeri; Kim, Youngjae; Yoon, Seulki; Sawant, Vikram Shahaji; Choi, Ji Won; Park, Jong Hyun; Park, Ki Duk; Min, Sun Joon; Lee, Changjoon; Choo, Hyunah.

In: ACS Chemical Neuroscience, Vol. 8, No. 7, 19.07.2017, p. 1519-1529.

Research output: Contribution to journalArticle

Nam, MH, Park, M, Park, H, Kim, Y, Yoon, S, Sawant, VS, Choi, JW, Park, JH, Park, KD, Min, SJ, Lee, C & Choo, H 2017, 'Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease', ACS Chemical Neuroscience, vol. 8, no. 7, pp. 1519-1529. https://doi.org/10.1021/acschemneuro.7b00050
Nam, Min Ho ; Park, Moosung ; Park, Hyeri ; Kim, Youngjae ; Yoon, Seulki ; Sawant, Vikram Shahaji ; Choi, Ji Won ; Park, Jong Hyun ; Park, Ki Duk ; Min, Sun Joon ; Lee, Changjoon ; Choo, Hyunah. / Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease. In: ACS Chemical Neuroscience. 2017 ; Vol. 8, No. 7. pp. 1519-1529.
@article{d3f39936bab94c2699c4d881ede2c973,
title = "Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease",
abstract = "To develop novel, selective, and reversible MAO-B inhibitors for safer treatment of Parkinson's disease, benzothiazole and benzoxazole derivatives with indole moiety were designed and synthesized. Most of the synthesized compounds showed inhibitory activities against MAO-B and selectivity over MAO-A. The most active compound was compound 5b, 6-fluoro-2-(1-methyl-1H-indol-5-yl)benzo[d]thiazole with an IC50 value of 28 nM with no apparent effect on MAO-A activity at 10 μM. Based on the reversibility assay, compound 5b turned out to be fully reversible with over 95{\%} of recovery of enzyme activity after washout of the compound. Compound 5b showed a reasonable stability in human liver microsomes and did not affect the activities of CYP isozymes, suggesting an absence of high-risk drug-drug interaction. In an in vivo MPTP-induced animal model of Parkinson's disease, oral administration of compound 5b showed neuroprotection of nigrostriatal dopaminergic neurons as revealed by tyrosine hydroxylase staining and prevention of MPTP-induced parkinsonism as revealed by motor behavioral assay of vertical grid test. In summary, the novel, reversible, and selective MAO-B inhibitor compound 5b was synthesized and characterized. We propose compound 5b as an effective therapeutic compound for relieving parkinsonism.",
keywords = "benzothiazole, benzoxazole, MAO-B, MAO-B inhibitor, MPTP-induced animal model, Parkinson's disease",
author = "Nam, {Min Ho} and Moosung Park and Hyeri Park and Youngjae Kim and Seulki Yoon and Sawant, {Vikram Shahaji} and Choi, {Ji Won} and Park, {Jong Hyun} and Park, {Ki Duk} and Min, {Sun Joon} and Changjoon Lee and Hyunah Choo",
year = "2017",
month = "7",
day = "19",
doi = "10.1021/acschemneuro.7b00050",
language = "English",
volume = "8",
pages = "1519--1529",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease

AU - Nam, Min Ho

AU - Park, Moosung

AU - Park, Hyeri

AU - Kim, Youngjae

AU - Yoon, Seulki

AU - Sawant, Vikram Shahaji

AU - Choi, Ji Won

AU - Park, Jong Hyun

AU - Park, Ki Duk

AU - Min, Sun Joon

AU - Lee, Changjoon

AU - Choo, Hyunah

PY - 2017/7/19

Y1 - 2017/7/19

N2 - To develop novel, selective, and reversible MAO-B inhibitors for safer treatment of Parkinson's disease, benzothiazole and benzoxazole derivatives with indole moiety were designed and synthesized. Most of the synthesized compounds showed inhibitory activities against MAO-B and selectivity over MAO-A. The most active compound was compound 5b, 6-fluoro-2-(1-methyl-1H-indol-5-yl)benzo[d]thiazole with an IC50 value of 28 nM with no apparent effect on MAO-A activity at 10 μM. Based on the reversibility assay, compound 5b turned out to be fully reversible with over 95% of recovery of enzyme activity after washout of the compound. Compound 5b showed a reasonable stability in human liver microsomes and did not affect the activities of CYP isozymes, suggesting an absence of high-risk drug-drug interaction. In an in vivo MPTP-induced animal model of Parkinson's disease, oral administration of compound 5b showed neuroprotection of nigrostriatal dopaminergic neurons as revealed by tyrosine hydroxylase staining and prevention of MPTP-induced parkinsonism as revealed by motor behavioral assay of vertical grid test. In summary, the novel, reversible, and selective MAO-B inhibitor compound 5b was synthesized and characterized. We propose compound 5b as an effective therapeutic compound for relieving parkinsonism.

AB - To develop novel, selective, and reversible MAO-B inhibitors for safer treatment of Parkinson's disease, benzothiazole and benzoxazole derivatives with indole moiety were designed and synthesized. Most of the synthesized compounds showed inhibitory activities against MAO-B and selectivity over MAO-A. The most active compound was compound 5b, 6-fluoro-2-(1-methyl-1H-indol-5-yl)benzo[d]thiazole with an IC50 value of 28 nM with no apparent effect on MAO-A activity at 10 μM. Based on the reversibility assay, compound 5b turned out to be fully reversible with over 95% of recovery of enzyme activity after washout of the compound. Compound 5b showed a reasonable stability in human liver microsomes and did not affect the activities of CYP isozymes, suggesting an absence of high-risk drug-drug interaction. In an in vivo MPTP-induced animal model of Parkinson's disease, oral administration of compound 5b showed neuroprotection of nigrostriatal dopaminergic neurons as revealed by tyrosine hydroxylase staining and prevention of MPTP-induced parkinsonism as revealed by motor behavioral assay of vertical grid test. In summary, the novel, reversible, and selective MAO-B inhibitor compound 5b was synthesized and characterized. We propose compound 5b as an effective therapeutic compound for relieving parkinsonism.

KW - benzothiazole

KW - benzoxazole

KW - MAO-B

KW - MAO-B inhibitor

KW - MPTP-induced animal model

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85024833338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024833338&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.7b00050

DO - 10.1021/acschemneuro.7b00050

M3 - Article

C2 - 28332824

AN - SCOPUS:85024833338

VL - 8

SP - 1519

EP - 1529

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 7

ER -